$CLOV Balance Sheet | Understand Stock

$CLOV

$4.63 +$0.07 (1.54%) Close

$CLOV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Investment securities, available-for-sale (Amortized cost: 2026: $39,950; 2025: $23,231)
Investment securities, held-to-maturity (Fair value: 2026: $2,021; 2025: $1,779)
Accrued retrospective premiums
Other receivables
Healthcare receivables
Non-Insurance performance year receivable
Non-Insurance receivable
Surety bonds and deposits
Prepaid expenses
Other assets, current
Assets related to discontinued operations (Note 22)
Total current assets
Direct Contracting performance year receivable
Investment securities, available-for-sale (Amortized cost: 2026: $190,771; 2025: $186,464)
Investment securities, held-to-maturity (Fair value: 2026: $10,295; 2025: $12,495)
Equity method investment
Property and equipment, net
Operating lease right-of-use assets
Other intangible assets
Other assets, non-current
Total assets

Liabilities and Stockholders' Equity
Current liabilities:
Unpaid claims
Due to related parties, net
Direct Contracting performance year obligation
Direct Contracting payable
Accounts payable and accrued expenses
Accrued salaries and benefits
Deferred revenue
Operating lease liabilities
Current portion of notes and securities payable
Premium deficiency reserve
Other liabilities, current
Related party
Nonrelated party
Total other liabilities, current
Non-Insurance performance year obligation, current
Non-Insurance payable
Liabilities related to discontinued operations (Note 22)
Total current liabilities

Direct Contracting performance year obligation
Notes and securities payable, net of discounts and deferred issuance costs
Derivative liabilities
Warrants payable
Long-term operating lease liabilities
Other liabilities, non-current
Total liabilities
Convertible Preferred stock (Series Seed A, A-1, B, C, and D), $0.0001 par value; 0 and 155,387,025 shares authorized as of December 31, 2021, and 2020, respectively; 0 and 139,444,346 shares issued and outstanding as of December 31, 2021, and 2020, respectively; aggregate liquidation preference of $0 and $470,256 as of December 31, 2021, and 2020, respectively (1)
Stockholders' equity:
Common stock, value
Common Class A
Common Class B
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Less: Treasury stock, at cost; 1,893,793 and 14,730 shares held as of March 31, 2022, and December 31, 2021, respectively
Less: Treasury stock, at cost; 35,782,658 and 33,412,273 shares held at June 30, 2026 and December 31, 2025, respectively
Total stockholders' equity
Noncontrolling interest

Total liabilities and stockholders' equity

Comments